Esophageal motility disorders, especially EGJOO and type 3 achalasia, occur more frequently among adults aged 75 years and older.

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

A large percentage of patients with SSc screened positive for ARFID, reporting significant GI symptom burden and reduced HRQOL.

Compared with those with overweight and normal weight, people with obesity are more likely to report financial hardship.